The Oncology Institute (TOI)
(Delayed Data from NSDQ)
$1.12 USD
+0.06 (5.66%)
Updated May 1, 2024 04:00 PM ET
After-Market: $1.12 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth B Momentum B VGM
Balance Sheet
Fiscal Year End for The Oncology Institute, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 83 | 74 | 115 | 1 | 0 |
Receivables | 43 | 40 | 21 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 14 | 9 | 6 | 0 | 0 |
Other Current Assets | 4 | 7 | 11 | 0 | 0 |
Total Current Assets | 143 | 130 | 154 | 1 | 0 |
Net Property & Equipment | 11 | 9 | 4 | 0 | 0 |
Investments & Advances | 0 | 58 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 25 | 39 | 45 | 0 | 0 |
Deposits & Other Assets | 1 | 0 | 0 | 230 | 0 |
Total Assets | 209 | 262 | 203 | 231 | 0 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 14 | 9 | 16 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 14 | 15 | 14 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 35 | 30 | 30 | 0 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 6 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 87 | 81 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 6 | 69 | 220 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 152 | 138 | 99 | 226 | 0 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 204 | 186 | 167 | 5 | 0 |
Retained Earnings | -146 | -63 | -63 | 0 | 0 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 1 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 57 | 123 | 104 | 5 | 0 |
Total Liabilities & Shareholder's Equity | 209 | 262 | 203 | 231 | 0 |
Total Common Equity | 57 | 123 | 104 | 5 | 0 |
Shares Outstanding | 74.10 | 73.20 | 73.20 | 28.70 | NA |
Book Value Per Share | 0.77 | 1.68 | 1.42 | 0.17 | 0.00 |
Fiscal Year End for The Oncology Institute, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 83 | 87 | 39 | 55 |
Receivables | NA | 43 | 49 | 47 | 46 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 14 | 12 | 12 | 10 |
Other Current Assets | NA | 4 | 4 | 6 | 7 |
Total Current Assets | NA | 143 | 153 | 104 | 119 |
Net Property & Equipment | NA | 11 | 11 | 11 | 10 |
Investments & Advances | NA | 0 | 0 | 59 | 59 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 25 | 26 | 27 | 22 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 209 | 218 | 230 | 235 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 14 | 13 | 13 | 12 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 14 | 13 | 14 | 12 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 35 | 32 | 34 | 30 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 87 | 85 | 84 | 82 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 3 | 1 | 2 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 152 | 147 | 145 | 136 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 204 | 200 | 196 | 191 |
Retained Earnings | NA | -146 | -127 | -110 | -93 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 1 | 1 | 1 | 0 |
Total Shareholder's Equity | NA | 57 | 72 | 85 | 98 |
Total Liabilities & Shareholder's Equity | NA | 209 | 218 | 230 | 235 |
Total Common Equity | 0 | 57 | 72 | 85 | 98 |
Shares Outstanding | 74.30 | 74.10 | 73.70 | 72.90 | 73.70 |
Book Value Per Share | 0.00 | 0.77 | 0.97 | 1.16 | 1.34 |